Randomized trial of doxorubicin, bisantrene, and miltoxantrone in advanced breast cancer: A southwest oncology group study

Journal of the National Cancer Institute

Volumn 83, Issue 15, 1991, Pages 1077-1084

  Cowan, John D ^a   Neidhart, James ^b   Mcclure, Suzanne ^c   Coltman, Charles A ^d   Gumbart, Conrad ^e   Martino, Silvana ^f   Hutchins, Laura F ^g   Stephens, Ronald L ^h   Vaughan, Clarencen B ⁱ   Osborne, C Kent ^d,j  

^a Mountain Cancer Treatment Center ^*  (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ PROVIDENCE HOSPITAL   (United States)

^j Southwest Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISANTRENE; DOXORUBICIN; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTHRACENES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; COMPARATIVE STUDY; DOXORUBICIN; FEMALE; HUMAN; MIDDLE AGE; MITOXANTRONE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025786929     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.15.1077     Document Type: Article

References (45)

1. Paterson Ahg, Szafran O, Corntsh F, Et Al: Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 1:357-363, 1981
2. Powles Tj, Coombes Rc, Smith Ie, Et Al: Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:580-582, 1980
3. Carter Sk:Chemotherapy of breast cancer, current status. In Breast Cancer Trends in Research and Treatment (Heuson JC, Mattheien WH, Rozancweig M, eds). New York: Raven Press, 1976, pp 193-215
4. Carbone Pp, Tormey Dc: Combination chemotherapy for advanced disease. In Breast Cancer Advances in Research and Treatment (McGuire WL, ed). New York: Plenum, 1977, pp 165-215
5. Henderson Ic, Hayes Df, Come S, Et Al: New agents and new medical treatments for advanced breast cancer. Semin Oncol 14:34-64, 1987
6. Tormey Dc: Adriamycin in breast cancer. Cancer Chemother Rep (Part 3) 6:319-327, 1975
7. Hoogstraten B, George Sl, Samal B, Et Al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer. A Southwest Oncology Group Study. Cancer 38:13-20, 1976
8. Nemoto T, Rosner D, Diaz R, Et Al: Combination chemotherapy for metastatic breast cancer Comparison of multiple drug therapy with 5- fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy. Cancer 41:2073-2077, 1978
9. Taylor Sg, Gelber Rd: Experience of the Eastern Cooperative Onocol- ogy Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep 66:1954-1955, 1982
10. Young Rc, Ozols Rf, Myers Ce: The anthracycline antineoplastic drugs. N Engl J Med 305:139-153, 1981
11. Von Hoff Dd, La Yard Mw, Basa P, Et Al: Risk factors for doxorubicin- induced congestive heart failure. Ann Intern Med 91:710-717, 1979
12. r5 dihydro-l H-im- idazol-2-yl)-hydrazone)dihydrochloride (abstr 23). Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1980
13. Von Hoff Dd, Coltman CA Jr, Forseth B: Activity of 9-10 anthracenedicarboxaldehyde bis [(4, 5-dihydro-lH-imidazol-2-yl)hydra- zonejdihydrochloride (CL216, 942) in a human tumor cloning system. Leads for phase II trials in man. Cancer Chemother Pharmacol 6:141-144, 1981
14. Cowan Jd, Von Hoff Dd, Clark Gm: Comparative cytotoxicity of Adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. Invest New Drugs 1:139-144, 1983
15. Jones Se, Dean Jc, Young LA, et al: The human tumor clonogenic assay in human breast cancer. J Clin Oncol 3:92-97, 1985
16. Osborne Ck, Von Hoff Dd, Cowan Jd, et al: Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep 68:357360, 1984
17. Yap HY, Yap BS, Blumenschein GR, et al: Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res 43:14021404, 1983
18. Cavalu F, Gerard B, ten Bokkel Huinink W, et al: Phase II evaluation of bisantrene in metastatic breast cancer. Cancer Treat Rep 69:337-338, 1985
19. Holmes FA, Esparza L, Yap HY, et al: A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol 18:157—161, 1986
20. Ingle JN, Long HJ, Schutt AJ, et al: Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer. Am J Clin Oncol 9:379-381, 1986
21. Myers JW, Von Hoff DD, Kuhn JG, et al: Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs 1:85-88, 1983
22. Kofj i.fr J, Eble M: Mitoxantrone: A novel anthracycline derivative. Clin Pharm 7:574-581, 1988
23. Johnson RK, Zee-Cheng RK, Lee WW, et al: Experimental antitumor activity of aminoanthraquinones. CancerTreat Rep 63:425-439, 1979
24. Wallace RE, Murdock KC, Anzier RB, et al: Activity of a novel anthracenedione, 1, 4-dihydroxy-5, 8-bis(((2-[(2-hydroxyethyl)amino]ethyl)- amino])-9,-10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570-1574, 1979
25. Durr FE: Biologic and biochemical effects of mitoxantrone. Semin Oncol 11:3-10, 1984
26. v5-dihydro-l H-imidazol-2-yl)hy- drazone] dihydrochloride (CL216, 942). Cancer Res 41:3118-3121, 1981
27. Von Hoff DD, Coltman CA, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853-1855, 1981
28. Cornbleet MA, Stuart-Harris RC, Smith IE: Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol 20:1141-1146, 1984
29. Yap HY, Blumenschein GR, Schell FC, et al: Dihydroxyanthra- cenedione: A promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95:694-697, 1981
30. Levin M, Pandya KJ, Khandekar JD, et al: Phase II study of ' mitoxantrone in advanced breast cancer An Eastern Cooperative Oncology Group pilot study. CancerTreat Rep 68:1511-1512, 1984
31. Smalley R, Gams R: Phase II study of mitoxantrone in patients with metastatic breast carcinoma: A Southeastern Cancer Study Group project. CancerTreat Rep 67:1039-1040, 1983
32. Neidhart JA, Gochnchjr D, Roach R, et al: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4:672-677, 1986
33. Crossley RJ: Clinical safety and tolerance of mitoxantrone (Novantrone). CancerTreat Rev 10:29-36, 1983
34. Posner LE, Dukart G, Goldberg J. et al: Mitoxantrone: An overview of safety and toxicity. Invest New Drugs 3:123-132, 1985
35. Sparano BM, Gordon G, Hall C, et al: Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin. II. Histologic and ultrastructural pathology. CancerTreat Rep 66:1145-1158, 1982
36. Coleman RE, Maisey MN, Knight RK, et al: Mitoxantrone in advanced breast cancer—a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20:771-776, 1984
37. Stuart-Harris R, Pearson M, Smith IE, et al: Cardiotoxicity associated with mitoxantrone. Lancet 2:219-220, 1984
38. Unverferth DV, Unverferth BJ, Balcerzak SP, et al: Cardiac evaluation of mitoxantrone. CancerTreat Rep 67:343-350, 1983
39. Benjamin RS, Clawla SP, Ewer MS, et al: Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update. Invest New Drugs 3:117-121, 1985
40. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
41. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
42. Cox DR: Regression models and life tables. J R Stat Soc B34:187-220, 1972
43. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
44. Henderson IC, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:560-571, 1989
45. Fleming TR: Treatment evaluation in active control studies. Cancer Treat Rep71:1061-1065, 1987